ENTITY
BeiGene

BeiGene (6160 HK)

438
Analysis
Health Care • China
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bearish•Softbank Group
•05 Nov 2018 06:03

Last Week in GER Research: Softbank, Babytree, Tencent Music, MYOB, Yancoal, Spotify Warning & More!

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.Ā  Last week, Arun initiated IPO coverage...

Logo
390 Views
Share
•01 Nov 2018 14:21

Innovent Biologics (äæ”č¾¾ē”Ÿē‰©) Post IPO: Hit Our TP, What's Next?

Innovent Biologics was priced at theĀ highĀ end and itĀ started trading yesterday (November 1st). It traded up by 18.5% on the first day and 8% on the...

Logo
821 Views
Share
•31 Oct 2018 16:39

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recentĀ spell of lacklustre early-stage biotech flotations that have slumpedĀ post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Logo
666 Views
Share
bearish•Babytree Group
•27 Oct 2018 16:59

Last Week in GER Research: A Dancing Tesla, Babytree, Mobvista, TuanChe and Pintec

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we recap on polarizedĀ Tesla Motors...

Logo
502 Views
Share
bearish•Tencent
•20 Oct 2018 19:18

Last Week in GER Research: Tencent Backed IPOs, Niu, Innovent Biologics, Babytree and Fujifilm

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we highlight a very differentiated...

Logo
747 Views
Share
x